Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Xiling Lab

    • Home
    • Xiling Lab
Company Deals

Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing

Fineline Cube Nov 25, 2022

Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close...

Company Deals

Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development

Fineline Cube Jun 24, 2022

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...

Recent updates

  • Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline
  • NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines
  • Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib
  • NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications
  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Company

Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib

Policy / Regulatory

NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.